{"entity":{"id":"nct04776655","kind":"trial","name":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","aka":["LIBImAb"],"tldr":"A phase 3 trial of bevacizumab (glioblastoma use), cetuximab, fluorouracil (5-FU) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Azienda USL Reggio Emilia - IRCCS, active but no longer recruiting.","summary":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB is a phase 3, randomised interventional study registered as NCT04776655 by Azienda USL Reggio Emilia - IRCCS, with a registry enrolment figure of 280 participants, started 2021-04-30 and due to reach its primary completion in 2025-05-04. Interventions recorded: Bevacizumab; Cetuximab; 5-FU; Irinotecan; Calcium levofolinate. Conditions listed: Colorectal Cancer; Metastatic Colorectal Cancer; RAS Mutation. Primary outcome: Progression free survival (PFS) in patients with RASmut at liquid biopsy and RASwt on tissue.. Colorectal eligibility wording from the registry: \"Histologically confirmed diagnosis of colorectal adenocarcinoma RAS/BRAF wild type (analysed either on primary and/or related metastasis);\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04776655","url":"https://clinicaltrials.gov/study/NCT04776655"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","topoisomerase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","cetuximab","fluorouracil","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04776655","phase":"3","setting":"Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)","sponsor":"Azienda USL Reggio Emilia - IRCCS","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04776655/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}